NCT04292340 is a clinical trial in Coronavirus, sponsored by Shanghai Public Health Clinical Center.

Who is sponsoring NCT04292340?

NCT04292340 is sponsored by Shanghai Public Health Clinical Center.

What condition does NCT04292340 study?

NCT04292340 studies Coronavirus.

Is NCT04292340 still recruiting?

NCT04292340 is currently status unknown. Last updated 3 March 2020.

Last reviewed 2020-03-03 · How we verify

NCT04292340

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19

Status unknown Last updated 3 March 2020

What this trial tests

trial in Coronavirus in 15 participants. Status unknown.

Timeline

1 February 2020

Primary endpoint
31 July 2020

31 December 2020

Quick facts

Lead sponsor	Shanghai Public Health Clinical Center
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	15
Start date	1 February 2020
Primary completion	31 July 2020
Estimated completion	31 December 2020
Sites	1 location across China

Conditions studied

Coronavirus — all drugs for Coronavirus →

Sponsor

Shanghai Public Health Clinical Center

Who can join

Eligibility, any sex, with Coronavirus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There is still no effective antiviral drugs and vaccines against SARS-CoV-2 yet now. This is an obsevational study, the investigators collected the clinical information and clinical outcomes of the COVID-19 patients using anti-2019-nCoV inactivated convalescent plasma.The study is to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of COVID-19 pneumonia.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Liu B, Li M, Zhou Z, Guan X, et al · · 2020 · cited 507× · PMID 32291137 · DOI 10.1016/j.jaut.2020.102452
The epidemiology, diagnosis and treatment of COVID-19.
Zhai P, Ding Y, Wu X, Long J, et al · · 2020 · cited 461× · PMID 32234468 · DOI 10.1016/j.ijantimicag.2020.105955
COVID-19: Transmission, prevention, and potential therapeutic opportunities.
Lotfi M, Hamblin MR, Rezaei N. · · 2020 · cited 447× · PMID 32474009 · DOI 10.1016/j.cca.2020.05.044
Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.
Ye M, Fu D, Ren Y, Wang F, et al · · 2020 · cited 265× · PMID 32293713 · DOI 10.1002/jmv.25882
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V, Chai KL, Valk SJ, Doree C, et al · · 2020 · cited 148× · PMID 32648959 · DOI 10.1002/14651858.cd013600.pub2
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Valk SJ, Piechotta V, Chai KL, Doree C, et al · · 2020 · cited 126× · PMID 32406927 · DOI 10.1002/14651858.cd013600
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V, Iannizzi C, Chai KL, Valk SJ, et al · · 2021 · cited 106× · PMID 34013969 · DOI 10.1002/14651858.cd013600.pub4
Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients.
Bonam SR, Kaveri SV, Sakuntabhai A, Gilardin L, et al · · 2020 · cited 91× · PMID 32562483 · DOI 10.1016/j.xcrm.2020.100016

Verify or expand the search:

Other recruiting trials for Coronavirus

Currently open trials in the same condition.

NCT04772170 — Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies · recruiting
NCT05868239 — Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study · NA · recruiting
NCT04359836 — A Study to Explore the Role of Gut Flora in COVID-19 Infection · recruiting
NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting
NCT04568148 — COVID-19 Biorepository · active not recruiting

Other Shanghai Public Health Clinical Center trials

Trials by the same sponsor.

NCT07526363 — Real-world Cohort Study of Antiretroviral Therapy in HIV Patients With Opportunistic Infections · not yet recruiting
NCT06940375 — Incidence of Liver Disease-Related Outcomes in People With HIV · recruiting
NCT06926569 — Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis · NA · not yet recruiting
NCT06768697 — Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant · EARLY_PHASE1 · not yet recruiting
NCT05129189 — Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04292340 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Public Health Clinical Center
Last refreshed: 3 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04292340.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing